TITLE

Update on Antifolate Drugs Targets

AUTHOR(S)

Costi, M.P.; Ferrari, S.

PUB. DATE

June 2001

SOURCE

Current Drug Targets;Jun2001, Vol. 2 Issue 2, p135

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Antifolate drugs are molecules directed to interfere with the folate metabolic pathway at some level. They can be recognized among the first rationally designed compounds applying the principle of structural analogy with the substrate developing the antimetabolite strategy. This strategy has taken advantage of the basic different features of the microbial and human folate metabolism and therefore allows targeting the pathway at different steps generating a specificity tools for Medicinal Chemists. Two main problems are giving renewed importance to such targets and therefore improving the efforts to discover new targets in the folate metabolism area. The first one is the increasing resistance to the present drugs due to different mechanisms such as the enzyme modification and the increased production of enzymes with not well recognized importance. The second one is the development of techniques directed to highlight the interference at genetic level of molecular probes as antifolate drug to develop new enzymes previously unknown. This approach is defined as genetic approach to drug discovery, from gene to drugs. The present article describes the importance in drug design and discovery of some antifolate targets among the best known at the present status of research such as thymidylate synthase (TS), dhydrofolate reductases, (DHFR) serine hydroxymethyltransferase (SHMT), folyilpolyglutamyl synthetase (FPGS), g-glutamyl hydrolase (g-GH), glycinamide-ribonucleotide transformylase (GARTfase), amino-imidazole-carboxamide-ribonucleotide transformylase (AICARTfase) and Folate transporters. Discovery, known functions, structure/function studies and inhibition will be described.

ACCESSION #

11134562

Tags: DRUGS -- Design;  DRUG targeting

 

Related Articles

• Targeting RNA with Small Molecules. Wilson, W. David; Ke Li // Current Medicinal Chemistry;Jan2000, Vol. 7 Issue 1, p73 

  Therapeutic targeting of RNA is not as well-developed as with DNA and proteins, and the many structures and functions of RNA suggest that it is an underutilized target. As with DNA, RNA has heterocyclic bases and base pairs with a highly anionic backbone, but as with proteins, RNA can fold into...

• Antimalarial Drug Discovery: In Silico Structural Biology and Rational Drug Design. De Beer, T. A. P; Wells, G. A.; Burger, P. B.; Joubert, F.; Marechal, E.; Birkholtz, L.; Louw, A. I. // Infectious Disorders - Drug Targets;Jun2009, Vol. 9 Issue 3, p304 

  Malaria remains one of the most burdensome human infectious diseases, with a high rate of resistance outbreaks and a constant need for the discovery of novel antimalarials and drug targets. For several reasons, Plasmodial proteins are difficult to characterise structurally using traditional...

• Nociceptin/Orphanin FQ Peptide Receptor as a Therapeutic Target for Obesity. Przydzial, Magdalena J.; Heisler, Lora K. // Mini Reviews in Medicinal Chemistry;Jul2008, Vol. 8 Issue 8, p796 

  Nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor is a candidate target for novel therapeutics for a range of conditions, including obesity. This article reviews recent advances in understanding of N/OFQ's involvement in the regulation of food intake and appraises current developments in the...

• Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation. Ying Wang; Jen-Fu Chiu; Qing-Yu He // Current Bioinformatics;Jan2007, Vol. 2 Issue 1, p11 

  Novel biomarker identification and drug target validation are highly complex and resource-intensive processes, requiring an integral use of various tools, approaches and information. The recently developed proteomic technology features high-throughput parallel analysis of thousands of proteins...

• A global view of drug-therapy interactions. Nacher, Jose c.; Schwartz, Jean-Marc // BMC Pharmacology;2008, Vol. 8, Special section p1 

  Background: Network science is already making an impact on the study of complex systems and offers a promising variety of tools to understand their formation and evolution in many disparate fields from technological networks to biological systems. Even though new high-throughput technologies...

• Virtual screening using chemical feature-based pharmacophores and virtual molecule libraries. Wolber, Gerhard; Langer, Thierry // Pharmaceutical Technology Europe;Apr2006, Vol. 18 Issue 4, p65 

  The article explores the virtual library generation combined with 3D pharmacophore screening to help accelerate drug discovery and assess typical risks of failure at later development stages. The authors explain that pharmacophores describing drug-target interaction is a biological activity in...

• Evaluation of teicoplanin dosing designs to achieve a new target trough concentration. Ueda, Takashi; Takesue, Yoshio; Nakajima, Kazuhiko; Ichki, Kaoru; Wada, Yasunao; Tsuchida, Toshie; Takahashi, Yoshiko; Ishihara, Mika; Tatsumi, Sumiyo; Kimura, Takeshi; Ikeuchi, Hiroki; Uchino, Motoi // Journal of Infection & Chemotherapy;Jun2012, Vol. 18 Issue 3, p296 

  Minimum inhibitory concentration (MIC) creep in vancomycin has prompted guidelines that recommend a target trough concentration ( C) of 15-20 mg/L, and it is also considered necessary to set a C of >15 mg/L for teicoplanin (TEIC), especially in patients with complicated methicillin-resistant...

• How to Efficiently Include Receptor Flexibility During Computational Docking. May, Andreas; Sieker, Florian; Zacharias, Martin // Current Computer-Aided Drug Design;Jun2008, Vol. 4 Issue 2, p143 

  Target-based drug design uses available 3D structural information of receptor molecules to either dock putative ligand molecules to receptor binding sites or to de-novo design new ligands. In many cases accurate prediction of putative binding geometries requires the appropriate inclusion of...

• NAD(P) Biosynthesis Enzymes as Potential Targets for Selective Drug Design. Magni, G.; Di Stefano, M.; Orsomando, G.; Raffaelli, N.; Ruggieri, S. // Current Medicinal Chemistry;Apr2009, Vol. 16 Issue 11, p1372 

  NAD(P) biosynthetic pathways can be considered a generous source of enzymatic targets for drug development. Key reactions for NAD(P) biosynthesis in all organisms, common to both de novo and salvage routes, are catalyzed by NMN/NaMN adenylyltransferase (NMNAT), NAD synthetase (NADS), and NAD...

Read the Article